Last reviewed · How we verify
Gemcitabine combined with Aptinib and Toripalimab
Gemcitabine combined with Aptinib and Toripalimab is a Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 1 development.
At a glance
| Generic name | Gemcitabine combined with Aptinib and Toripalimab |
|---|---|
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine combined with Aptinib and Toripalimab CI brief — competitive landscape report
- Gemcitabine combined with Aptinib and Toripalimab updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Gemcitabine combined with Aptinib and Toripalimab
What is Gemcitabine combined with Aptinib and Toripalimab?
Gemcitabine combined with Aptinib and Toripalimab is a Small molecule drug developed by Sun Yat-sen University.
Who makes Gemcitabine combined with Aptinib and Toripalimab?
Gemcitabine combined with Aptinib and Toripalimab is developed by Sun Yat-sen University (see full Sun Yat-sen University pipeline at /company/sun-yat-sen-university).
What development phase is Gemcitabine combined with Aptinib and Toripalimab in?
Gemcitabine combined with Aptinib and Toripalimab is in Phase 1.